Theras, Inc., D/b/a Bbot (bridgebio Oncology Therapeutics)
Clinical trials sponsored by Theras, Inc., D/b/a Bbot (bridgebio Oncology Therapeutics), explained in plain language.
-
New drug targets multiple KRAS mutations in advanced cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called BBO-11818 in people with advanced cancers that have specific KRAS gene mutations. The study aims to find a safe dose and see if the drug can shrink tumors in cancers like lung, pancreatic, and colorectal cancer. Participants wil…
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for Tough-to-Treat lung cancer: first patients test novel drug
Disease control Recruiting nowThis is the first study in people to test a new drug called BBO-8520 for advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The main goals are to find a safe dose and see if the drug can help shrink tumors. The study will test BBO-8520 alone …
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
First human trial launches for experimental cancer 'Breaker' drug
Disease control Recruiting nowThis is the first human study testing a new experimental drug called BBO-10203 in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to find safe doses and see how the body processes the drug, both alone and when combined with oth…
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC